Why the study?
Although views on estrogen degradation metabolites (EDMs) have changed, unknowns remain regarding their effects on the heart after findings showed they affect isolated cardiac mitochondria.
Population
Rat H9c2 cardiomyoblast cells and intact and oophorectomized female rats
Comparison
Exposure to Met A (2-hydroxyestrone) vs Met D (17β-estradiol-3-methyl-ether)
Design
In vitro and in vivo animal experimental study
Key result
Exposure to estrogen degradation metabolites, particularly Met D, significantly decreased antioxidant capacity and increased oxidative stress, leading to cardiac hypertrophy and fibrosis.
Authors
Loading...
Met D may promote oxidative stress, hypertrophy, and fibrosis in estrogen-deficient rat hearts despite preserved function; leaves open human relevance and requires prospective study.
Exogenous estrogenic metabolites, particularly 17β-estradiol-3-methyl-ether, induce oxidative stress, cardiac hypertrophy, and fibrosis in female rat models without altering echocardiographic cardiac function.
Silva‐Palacios et al. (2026) studied this question. Estrogen degradation metabolites (Met A and Met D) was evaluated on Cell viability, mitochondrial potential, oxidative stress, and cardiac function/histology. Exposure to estrogen degradation metabolites, particularly Met D, significantly decreased antioxidant capacity and increased oxidative stress, leading to cardiac hypertrophy and fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: